Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis

医学 内科学 中止 放射治疗 不利影响 肿瘤科 乳腺癌 毒性 荟萃分析 癌症 转移性乳腺癌 胃肠病学
作者
Marcin Kubeczko,Michał Jarząb,Dorota Gabryś,Aleksandra Krzywon,Alexander Jorge Cortez,Amy J. Xu
出处
期刊:Radiotherapy and Oncology [Elsevier BV]
卷期号:187: 109839-109839 被引量:1
标识
DOI:10.1016/j.radonc.2023.109839
摘要

Background and PurposeThe addition of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy in hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2-) breast cancer has led to practice-changing improvements in overall survival. However, there are conflicting data concerning the safety of CDK4/6i combination with radiotherapy, and no consensus guidelines exist to guide practice. We conducted a meta-analysis to assess the safety and feasibility of CDK4/6i treatment with radiotherapy.Materials and MethodsA comprehensive search was performed in PubMed/MEDLINE, Web of Science, and Scopus, for studies in advanced/metastatic breast cancer receiving CDK4/6i and radiotherapy with the provided safety data on the occurrence of toxicity. The main outcomes were safety (grade 3-5 adverse events), CDK 4/6i dose reduction, and the discontinuation rate due to toxicity.ResultsFifteen studies comprising 1133 patients with HR+/HER2- breast cancer patients were included. Among them, 617 pts received CDK4/6i and radiotherapy; the median follow-up was 17.0 months (IQR 9.2 – 18.0), and the median age was 58.8 years (IQR 55.5 - 62.5). The pooled prevalence of severe hematologic toxicity was 29.4% (95% CI 14.0% – 47.4%; I2 = 93%; τ2 = 0.084; p < 0.01 and severe non-hematologic toxicity was 2.8% (95% CI 1.1% – 4.8%; I2 = 0%; τ2 = 0.0; p = 0.67). The pooled prevalence of CDK4/6i dose reduction was 24.0% (95% CI 11.1% – 39.4%; I2 = 90%; τ2 = 0.052; p < 0.01) with no difference between CDK4/6i plus RT vs. CDK4/6i (odds ratio of 0.934; 95% CI 0.66 – 1.33; I2 = 0%; τ2 = 0.0; p = 0.56). The pooled prevalence of CDK4/6i discontinuation due to toxicity was 2.3% (95% CI 0.4% – 5.2%; I2 = 23%; τ2 = 0.002; p = 0.24).ConclusionThe findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
笨笨松发布了新的文献求助10
刚刚
该换手机完成签到,获得积分10
刚刚
万能图书馆应助zzd采纳,获得10
1秒前
3秒前
隐形曼青应助CC悟了采纳,获得10
3秒前
4秒前
玩命的灵含完成签到,获得积分20
4秒前
小马甲应助yang采纳,获得10
4秒前
星辰大海应助sbw采纳,获得10
4秒前
LienAo完成签到 ,获得积分10
5秒前
6秒前
6秒前
71完成签到,获得积分10
7秒前
7秒前
烟花应助科研菜鸡623采纳,获得10
8秒前
8秒前
11秒前
Kailee发布了新的文献求助10
11秒前
奇异完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助10
13秒前
zhhua完成签到,获得积分10
13秒前
所所应助星星采纳,获得10
14秒前
DD应助玩命的灵含采纳,获得10
14秒前
在水一方应助如意的听云采纳,获得10
14秒前
瓜瓜瓜完成签到,获得积分10
14秒前
澡雪发布了新的文献求助10
15秒前
liu关注了科研通微信公众号
15秒前
兴奋的万声完成签到,获得积分10
16秒前
上官若男应助盛夏如花采纳,获得10
17秒前
17秒前
pluto应助内向薯片采纳,获得30
17秒前
于是发布了新的文献求助10
17秒前
天天快乐应助机灵笑萍采纳,获得10
17秒前
风趣的老太应助yudiao采纳,获得10
18秒前
开心的访云完成签到,获得积分10
18秒前
Jiang 小白完成签到,获得积分10
19秒前
19秒前
张雷完成签到,获得积分10
19秒前
小豆豆应助可乐冰淇淋采纳,获得20
19秒前
Uload完成签到,获得积分20
19秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975693
求助须知:如何正确求助?哪些是违规求助? 3520019
关于积分的说明 11200635
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798255
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390